|Bid||10.80 x 1200|
|Ask||13.40 x 800|
|Day's Range||13.56 - 14.99|
|52 Week Range||3.70 - 18.00|
|Beta (5Y Monthly)||2.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug 28, 1996|
|1y Target Est||18.00|
CEL-SCI reports recent data review by the Independent Data Monitoring Committee for its pivotal Phase 3 head and neck cancer study.
CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center for Vaccines and Immunology
Oil stocks are extend their losing streak into day five as fears of the coronavirus continue. Blue Line Futures President Bill Baruch joins Yahoo Finance’s On the Move to discuss.
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT The Last Review? CEL-SCI Corporation (NYSE:CVM) today announced its second Independent Data Monitoring Committee (IDMC) review this year for the IT MATTERS Phase III Multikine study for head and neck cancer. We believe that the longer than expected duration of the trial combined with the IDMC recommendation to continue its